Biotech · Private company

TransThera Sciences (Nanjing), Inc.

Track this companyFree. Adds TransThera Sciences (Nanjing), Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials91 recruiting or active

Pipeline programs12From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline12

Physician's ChoicePhase 3 · CholangiocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Tinengotinib 10 mgPhase 3 · CholangiocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Tinengotinib 8 mgPhase 3 · CholangiocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
Nab-PaclitaxelPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
TT-00420Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
TT-00420Phase 2 · CholangiocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
TT-00420Phase 1 · Advanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
TT-00420 CapsulePhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
TT-00420 TabletPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
TT-00920Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
TT-01488Phase 1 · B-Cell MalignanciesClinicalTrials.gov · fetched Nov 12, 2026
TinengotinibAdvanced Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials9

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in CholangiocarcinomaPHASE3 · ACTIVE_NOT_RECRUITING · started Dec 20, 2023ClinicalTrials.gov NCT05948475 · fetched Nov 12, 2026
Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell MalignanciesPHASE1 · UNKNOWN · started Jun 1, 2022ClinicalTrials.gov NCT05275504 · fetched Nov 12, 2026
Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in CholangiocarcinomaPHASE2 · COMPLETED · started Dec 7, 2021ClinicalTrials.gov NCT04919642 · fetched Nov 12, 2026
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Dose of TT-00920 in Healthy SubjectsPHASE1 · COMPLETED · started Aug 19, 2021ClinicalTrials.gov NCT05043792 · fetched Nov 12, 2026
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsPHASE1_PHASE2 · COMPLETED · started Mar 14, 2021ClinicalTrials.gov NCT04742959 · fetched Nov 12, 2026
Relative Bioavailability Study and Food Effect Study of TT-00420 (Tinengotinib) Capsule and Tablet Formulations in Healthy VolunteersPHASE1 · COMPLETED · started Dec 29, 2020ClinicalTrials.gov NCT04705922 · fetched Nov 12, 2026
Phase I, First-In-Human Study of TT-00920 in Healthy SubjectsPHASE1 · COMPLETED · started Feb 5, 2020ClinicalTrials.gov NCT04364789 · fetched Nov 12, 2026
Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast CancerPHASE1 · COMPLETED · started Jan 8, 2019ClinicalTrials.gov NCT03654547 · fetched Nov 12, 2026
Rollover Study to Provide Continued Access to TT-00420 (Tinengotinib) for Subjects With Advanced Solid TumorsAVAILABLEClinicalTrials.gov NCT06370013 · fetched Nov 12, 2026